Journal article
Role of genetic testing in hepatic, pancreatic, and biliary cancers
Surgical oncology, Vol.44, pp.101844-101844
09/01/2022
DOI: 10.1016/j.suronc.2022.101844
PMID: 36116416
Abstract
Hepatic, pancreatic, and biliary (HPB) cancers, including hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma (CCA) cause a disproportionate amount of the global cancer -related mortality. Despite advances in surgical technique and improved systemic therapies, overall 5-year sur-vival remains dismal, especially for patients with pancreatic and biliary cancer. Historically, systemic therapies for patients with HPB cancers were administered in a "one-size-fits-all" approach due to limited reliable data on efficacy for specific patient populations. However, recent advances in genetic testing techniques have greatly improved our understanding of HPB oncogenesis, shedding light on specific genetic mutations responsible for progression from physiologic cellular regulation to uninhibited cellular replication and invasive cancer. In-vestigations into the oncogenesis of HPB cancers have revealed multiple actionable genetic variants, as well as increased susceptibilities to currently available systemic therapies. For example, patients with PDAC and a known BRCA mutation are more likely to benefit from FOLFIRINOX or gemcitabine plus cisplatin. While patients with CCA and a IDH1 mutation may benefit from ivosidenib. As a result, many national and societal guidelines now recommend some form of genetic testing in the workup of patients with HPB cancers. We herein review the role of genetic testing in these aggressive cancers including DNA sequencing techniques, clinically relevant mutations, therapeutic implications, and current clinical recommendations.
Details
- Title: Subtitle
- Role of genetic testing in hepatic, pancreatic, and biliary cancers
- Creators
- D. Brock Hewitt - The Ohio State University Wexner Medical CenterHassan Aziz - University Medical CenterZachary J. Brown - The Ohio State University Wexner Medical CenterTimothy M. Pawlik - The Ohio State University Wexner Medical Center
- Resource Type
- Journal article
- Publication Details
- Surgical oncology, Vol.44, pp.101844-101844
- Publisher
- Elsevier
- DOI
- 10.1016/j.suronc.2022.101844
- PMID
- 36116416
- ISSN
- 0960-7404
- eISSN
- 1879-3320
- Number of pages
- 8
- Language
- English
- Date published
- 09/01/2022
- Academic Unit
- Surgery
- Record Identifier
- 9984701644802771
Metrics
5 Record Views